Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025GlobeNewsWire • 11/05/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYEPRNewsWire • 10/28/25
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical OfficerGlobeNewsWire • 10/28/25
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II GoalZacks Investment Research • 10/07/25
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical TrialGlobeNewsWire • 10/06/25
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual MeetingGlobeNewsWire • 09/19/25
Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
Skye Bioscience Advances Position In Competitive Obesity Market With Promising DataBenzinga • 09/05/25
Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO ModelGlobeNewsWire • 09/04/25
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data ReadoutGlobeNewsWire • 08/27/25
Skye Bioscience to Participate in Upcoming Investment and Medical ConferencesGlobeNewsWire • 08/21/25
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 08/07/25
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025GlobeNewsWire • 07/30/25
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific SessionsGlobeNewsWire • 06/23/25